Alzheimer's Disease (AD) in elderly adds substantially to socio-economic burden necessitating early diagnosis. While recent studies in rodent models of AD have suggested diagnostic and therapeutic value for gamma rhythms in brain, the same has not been rigorously tested in humans. In this case-control study, we recruited a large population (N=244; 106 females) of elderly (>49 years) subjects from the community, who viewed large gratings that induced strong gamma oscillations in their electroencephalogram (EEG). These subjects were classified as healthy (N=227), mild-cognitively-impaired (MCI; N=12) or AD (N=5) based on clinical history and Clinical Dementia Rating scores. Surprisingly, stimulus-induced gamma rhythms, but not alpha or steady-state visually evoked responses, were significantly lower in MCI/AD subjects compared to their age and gender matched controls. This reduction was not due to differences in eye-movements or baseline power. Our results suggest that gamma could be used as potential screening tool for MCI/AD in humans.
AbstractGamma rhythms (∼20-70 Hz) have been reported to be abnormal in mental disorders such as autism and schizophrenia in humans, and Alzheimer’s disease (AD) models in rodents. However, the effect of normal aging on these oscillations is not known, especially for elderly subjects (>49 years) for which AD is most prevalent. In a first large-scale (236 subjects; 104 females) electroencephalogram (EEG) study on gamma oscillations on elderly subjects (aged 50-88 years), we presented full-screen Cartesian gratings that induced two distinct gamma oscillations (slow: 20-34 Hz and fast: 36-66 Hz). Power and centre frequency significantly decreased with age for both slow and fast gamma, but not alpha (8-12 Hz). Reduction was more salient for fast gamma than slow. These results were independent of microsaccades and pupillary reactivity to stimulus, as well as variations in power spectral density with age. Steady-state visual evoked potentials (SSVEPs) also reduced with age. These results are crucial first steps towards using gamma/SSVEPs as biomarkers of cognitive decline in elderly.Significance statementNo study in humans has examined visual narrow-band gamma oscillations with healthy aging in elderly subjects. In a first large-scale (236 subjects) EEG study on stimulus-induced narrow band gamma in cognitively normal elderly (>49 years) humans, we show that both power and centre frequency of slow and fast gamma (20-34 Hz and 36-66 Hz respectively) decrease with age, but alpha power does not. Steady-state visual evoked potential (SSVEPs) in gamma range also decrease with age. Any EEG-based biomarker is accessible and affordable to patients of a wide socio-economic spectrum. Our results are important steps for developing such screening/diagnostic tests for aging-related diseases, like Alzheimer’s disease.
As we look around the world, selecting our targets, competing events may occur at other locations. Depending on current goals, the viewer must decide whether to look at new events or to ignore them. Two experimental paradigms formalize these response options: double-step saccades and saccadic inhibition. In the first, the viewer must reorient to a newly appearing target; in the second, they must ignore it. Until now, the relationship between reorienting and inhibition has been unexplored. In three experiments, we found saccadic inhibition ∼100 msec after a new target onset, regardless of the task instruction. Moreover, if this automatic inhibition is boosted by an irrelevant flash, reorienting is facilitated, suggesting that saccadic inhibition plays a crucial role in visual behavior, as a bottom-up brake that buys the time needed for decisional processes to act. Saccadic inhibition may be a ubiquitous pause signal that provides the flexibility for voluntary behavior to emerge.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.